MINAPHARM Pharmaceuticals (EGX:MIPH)

MINAPHARM Pharmaceuticals Balance Sheet

Financials in millions EGP. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,818	2,885	1,918	1,694	981.94	1,024
Short-Term Investments	5	5	-	-	-	-
Cash & Short-Term Investments	3,823	2,890	1,918	1,694	981.94	1,024
Cash Growth	19.63%	50.70%	13.25%	72.47%	-4.06%	33.96%
Accounts Receivable	720.13	647.52	492.9	478.14	388.76	331.91
Other Receivables	175.49	76.37	46.13	12.22	5.52	5.67
Receivables	895.61	1,005	742.76	575.06	399.59	358.93
Inventory	1,324	1,233	1,055	838.28	668.51	587.16
Prepaid Expenses	641.4	30.33	10.76	12.41	6.54	5.89
Other Current Assets	-	558.59	315.92	524.8	345.77	205.54
Total Current Assets	6,684	5,717	4,042	3,644	2,402	2,181
Property, Plant & Equipment	6,114	5,687	4,251	2,685	1,340	1,004
Long-Term Investments	-	-	5	5	5	5
Goodwill	339.97	339.97	334.51	280.08	220.53	230.21
Other Intangible Assets	236	254.84	67.1	56.9	48.2	62.16
Long-Term Deferred Tax Assets	-	-	-	-	-	0.81
Other Long-Term Assets	5.24	4.92	3.22	134.67	89.77	-
Total Assets	13,379	12,003	8,704	6,806	4,106	3,483
Accounts Payable	1,110	1,189	735.34	677.29	416.64	508.39
Accrued Expenses	274.35	47.34	46.81	39.23	31.53	26.18
Short-Term Debt	2,104	2,191	2,043	1,042	542.29	747.41
Current Portion of Long-Term Debt	504.52	398.09	218.67	225.33	32.93	23.24
Current Portion of Leases	73.52	55.35	27.77	15.1	68.13	-
Current Income Taxes Payable	185.5	195.94	134.82	233.36	183.69	151.54
Current Unearned Revenue	-	14.62	9.81	7.45	5.04	4.44
Other Current Liabilities	223.01	495.28	314.7	261.3	208.89	168.76
Total Current Liabilities	4,475	4,587	3,531	2,501	1,489	1,630
Long-Term Debt	2,206	2,250	1,335	1,036	603.87	187.84
Long-Term Leases	524.43	562.68	153.62	114.83	1.17	-
Long-Term Deferred Tax Liabilities	87.61	27.54	44.99	56.01	22.69	18.53
Other Long-Term Liabilities	150.3	167.5	121.15	57.52	45.73	53.43
Total Liabilities	7,443	7,594	5,186	3,765	2,163	1,890
Common Stock	117.81	117.81	122.93	122.93	122.93	122.93
Retained Earnings	2,046	2,053	2,147	2,023	1,466	1,047
Treasury Stock	-	-	-69.63	-69.63	-	-
Comprehensive Income & Other	3,664	2,135	1,222	882.83	293.27	367.67
Total Common Equity	5,828	4,306	3,423	2,959	1,882	1,537
Minority Interest	107.86	102.74	94.61	81.82	61.29	56.04
Shareholders' Equity	5,936	4,409	3,517	3,041	1,943	1,593
Total Liabilities & Equity	13,379	12,003	8,704	6,806	4,106	3,483
Total Debt	5,413	5,457	3,779	2,433	1,248	958.49
Net Cash (Debt)	-1,590	-2,566	-1,861	-739.64	-266.46	65.01
Net Cash Per Share	-107.48	-231.95	-168.18	-64.46	-21.67	5.29
Filing Date Shares Outstanding	16.68	11.78	11.06	11.06	12.29	12.29
Total Common Shares Outstanding	16.68	11.78	11.06	11.06	12.29	12.29
Working Capital	2,210	1,130	511.26	1,143	913.2	551.05
Book Value Per Share	349.40	365.53	309.35	267.42	153.07	125.04
Tangible Book Value	5,252	3,711	3,021	2,622	1,613	1,245
Tangible Book Value Per Share	314.87	315.04	273.05	236.96	131.21	101.26
Land	-	55.2	39.7	33.23	26.15	27.3
Buildings	-	1,579	508.65	411.79	296.6	307.09
Machinery	-	2,505	1,777	1,365	977.94	961.26
Construction In Progress	-	2,988	2,936	1,666	666.97	357.47

Source: S&P Global Market Intelligence. Standard template. Financial Sources.